CD320 and cancer: Research has shown that NRAS mutations in liver cancer are closely associated with tumor drug resistance.[18] Quadros et al[19] observed the overexpression of CD320 in multiple types of cancer and proposed that targeting the absorption of VB12 through the CD320 receptor and antibody-toxic conjugate may serve as a feasible treatment strategy for certain cancers with CD320 receptor overexpression.